Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy

Nephrology

Volumn 15, Issue 2, 2010, Pages 225-229

  Eyileten, Tayfun ^a   Sonmez, Alper ^a   Saglam, Mutlu ^a   Cakir, Erdinc ^a   Caglar, Kayser ^a   Oguz, Yusuf ^a   Vural, Abdulgaffar ^a   Yenicesu, Mujdat ^a   Yilmaz, Mahmut Ilker ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Endothelial dysfunction; Proteinuria; Type 2 diabetes mellitus; Visfatin

Indexed keywords

C REACTIVE PROTEIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RAMIPRIL;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; ENZYME BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CYTOKINES; DIABETIC NEPHROPATHIES; ENDOTHELIUM, VASCULAR; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEINURIA; RAMIPRIL; RENIN-ANGIOTENSIN SYSTEM; TIME FACTORS; TREATMENT OUTCOME; VASODILATION;

EID: 77749283806     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01173.x     Document Type: Article

References (28)

1. Warram JH, Laffel LM, Ganda OP, Christlieb AR. Coronary artery disease is the major determinant of excess mortality in patients with insulin-dependent diabetes mellitus and persistent proteinuria. J. Am. Soc. Nephrol. 1992 3 (4 Suppl 104 110.
2. Suliman ME, Yilmaz MI, Carrero JJ et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2008 3 : 976 985.
3. de Jager J, Dekker JM, Kooy A et al. Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study. Arterioscler. Thromb. Vasc. Biol. 2006 26 : 1086 1093.
4. Yilmaz MI, Saglam M, Qureshi AR et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol. Dial. Transplant. 2008 23 : 1621 1627.
5. Basi S, Lewis JB. Microalbuminuria as a target to improve cardiovascular and renal outcomes in diabetic patients. Curr. Diab. Rep. 2007 7 : 439 442.
6. Guzik TJ, Mangalat D, Korbut R. Adipocytokines - novel link between inflammation and vascular function? J. Physiol. Pharmacol. 2006 57 : 505 528.
7. Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol. Med. 2005 11 : 344 347.
8. Song HK, Lee MH, Kim BK et al. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2008 295 : 1485 1494.
9. Dogru T, Sonmez A, Tasci I et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res. Clin. Pract. 2007 76 : 24 9.
10. Yilmaz MI, Saglam M, Carrero JJ et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol. Dial. Transplant. 2008 23 : 959 965. (Pubitemid 351767576)
11. Axelsson J, Witasp A, Carrero JJ et al. circulating levels of visfatin/Pre-B-cell colony-enchancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am. J. Kidney Dis. 2007 49 : 237 244.
12. Remuzzi G, Perico N, Macia M et al. The role of renin-angiotensin- aldosterone system in the progression of chronic kidney disease. Kidney Int. Suppl. 2005 99 S57 S65.
13. Ruggenenti P, Perna A, Benini R et al. In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in remission. J. Am. Soc. Nephrol. 1999 10 : 997 1006.
14. Miyazaki Y, Murakami H, Hirata A et al. Effects of angiotensin converting enzyme inhibitor temocapril on insulin sensivity and its effects on renal sodium handling and the pressor system in essential hypertensive patients. Am. J. Hypertens. 1998 11 : 962 970.
15. Barra S, Vitagliano A, Cuomo V, Vitagliano G, Gaeta G. Vascular and metabolic effects of angiotensin II receptor blockers. Expert Opin. Pharmacother. 2009 10 : 173 189.
16. Segura J, Ruilope LM. Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr. 2007 10 : 1151 1155.
17. Yenicesu M, Yilmaz MI, Caglar K et al. Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria. Nephron Clin. Pract. 2005 99 : c115 21.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972 18 : 499 502.
19. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann. Intern. Med. 1999 130 : 461 470.
20. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 : 412 419.
21. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992 340 : 1111 1115.
22. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006 580 : 2917 2921.
23. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005 21 : 426 430. (Pubitemid 40139988)
24. Curat CA, Wegner V, Sengenes C et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006 49 : 744 777.
25. Jia SH, Li Y, Parodo J et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J. Clin. Invest. 2004 113 : 1318 1327.
26. Axelsson J, Stenvinkel P. Role of fat mass and adipokines in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2008 17 : 25 31.
27. Storka A, Vojtassakova E, Mueller M et al. Angiotensin inhibition stimulates PPARgamma and the release of visfatin. Eur. J. Clin. Invest. 2008 38 : 820 826.
28. Nakou E, Filippatos TD, Liberopoulos EN et al. Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin. Pharmacother. 2008 9 : 1629 1639.